Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Gushchin, Vladimir A.; Dolzhikova, Inna V.; Щетинин, А. М.; Одинцова, А. С.; Siniavin, Andrei E.; Никифорова, М. А.; Pochtovyi, Andrei A.; Shidlovskaya, Elena V.; Kuznetsova, Nadezhda A.; Бургасова, О. А.; Колобухина, Л. В.; Iliukhina, Anna A.; Kovyrshina, Anna V.; Ботиков, А. Г.; Kuzina, Aleksandra V.; Grousova, Daria M.; Tukhvatulin, Amir I.; Shcheblyakov, Dmitry V.; Zubkova, Olga V.; Карпова, О.В.; Voronina, Olga L.; Рыжова, Н. Н.; Aksenova, Ekaterina I.; Kunda, Marina S.; Lioznov, Dmitry; Danilenko, Daria; Komissarov, Andrey; Tkachuck, Artem P.; Logunov, Denis Y.; Gintsburg, Alexander L.

doi:10.3390/vaccines9070779

Cited by 104 publications

(79 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, a Russian study showed that the neutralising activity of sera from persons vaccinated with Sputnik V against the variants of concern was reduced [ 40 ]. For the Beta, Gamma and Delta variants, a statistically significant reduction in neutralising activity of 3.1, -2.8-, and 2.5-fold, respectively, was observed.…”

Section: Consmentioning

confidence: 99%

“…However, it should be noted that a study that used data on all symptomatic sequenced cases of COVID-19 in England to estimate the proportion of cases with Delta and Alpha variants according to the patients’ vaccination status, found that Comirnaty was 88.0% effective against symptomatic disease from the Delta variant two weeks after a second dose, compared to 93.7% effective against the Alpha strain, while Vaxzevria was 67.0% effective against the Delta variant, compared to 74.5% effective against the Alpha variant over the same period [ 53 ]. As already mentioned, the virus-neutralizing activity of sera obtained from people vaccinated with Sputnik V showed 2.5-fold reduction for Delta variant [ 40 ]. Although reductions in virus-neutralizing activity are not directly correlated to a vaccine’s overall effectiveness at preventing infection, antibody evasion of Delta variant may contribute to the rapid spread of this variant.…”

Section: Differentiation Between Sputnik V and Some Other Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Controversy surrounding the Sputnik V vaccine

Cazzola

Rogliani

Mazzeo

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in the effectiveness of the vaccination. Real life data indicate an efficacy of the vaccine above 97%. Low cost and no need for ultra-cold storage temperature temperatures are other pluses of the Sputnik V vaccine. However, there are also several important shortcomings that must be considered such as the possible reduction of its immunogenicity in the presence of very high Ad5 neutralizing antibody titres and the decrease with age of the antibody titres neutralizing the virus. Furthermore, there is emerging documentation that Sputnik V has a reduced neutralizing capacity against the Beta variant and all variants with the spike protein carrying the E484K substitution. Nevertheless, due to its characteristics, Sputnik V could be another useful means of satisfying the need for mass vaccination. However, it is imperative to document the efficacy and safety of the Sputnik V vaccine in individuals with high pre-existing anti-Ad26 and Ad5-neutralizing antibody titres and in those under the age of 18 or older than 60 years and be certain that Sputnik V does not cause the rare development of immune thrombotic thrombocytopenia. It is hoped that the now widespread use of this vaccine will generate a large pragmatic real-world study with data accessible to anyone interested in verifying them.

show abstract

Section: Consmentioning

confidence: 99%

Section: Differentiation Between Sputnik V and Some Other Vaccinesmentioning

confidence: 99%

Controversy surrounding the Sputnik V vaccine

Cazzola

Rogliani

Mazzeo

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…J&J observed similar antibody-neutralizing activity upon a single-dose of Ad26.COV2.S against this VOC as compared to the parental USA-WA1/2020 [141]. Similarly, Sputnik V full-vaccination induced equivalent neutralization titers against this variant as the reference strain B.1.1.1, locally endemic to Moscow [142].…”

Section: Effectiveness Of Adenovirus-based Vaccines Against Variantsmentioning

confidence: 73%

“…Real-world data from Canada showed that one dose with AZD1222 has a protective effectiveness of 82% against hospitalization or death from infection with Beta/Gamma [116]. Consistently to AZD1222, one-log reduction in the neutralization activity in sera from J&J vaccinated participants in comparison with the reference isolate and with sera from individuals fully vaccinated with Sputnik V, neutralization titers dropped by 3.1-fold [141,142]. This emphasizes the requirement of more specific vaccines against this variant.…”

Section: Effectiveness Of Adenovirus-based Vaccines Against Variantsmentioning

confidence: 85%

Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

et al. 2021

View full text Add to dashboard Cite

Since late 2019 the newly emerged pandemic SARS-CoV-2, the causative agent of COVID‑19, has hit the world with recurring waves of infections necessitating the global implementation of non-pharmaceutical interventions, including strict social distancing rules, the wearing of masks and the isolation of infected individuals in order to restrict virus transmissions and prevent the breakdown of our healthcare systems. These measures are not only challenging on an economic level but also have a strong impact on social lifestyles. Using traditional and novel technologies, highly efficient vaccines against SARS-CoV-2 were developed and underwent rapid clinical evaluation and approval to accelerate the immunization of the world population, aiming to end the pandemic and return to normality. However, the emergence of virus variants with improved transmission, enhanced fitness and partial immune escape from the first generation of vaccines poses new challenges, which are currently being addressed by scientists and pharmaceutical companies all over the world. In this ongoing pandemic, the evaluation of SARS-CoV-2 vaccines underlies diverse unpredictable dynamics, posed by the first broad application of the mRNA vaccine technology and their compliance, the occurrence of unexpected side effects and the rapid emergence of variations in the viral antigen. However, despite these hurdles, we conclude that the available SARS-CoV-2 vaccines are very safe and efficiently protect from severe COVID-19 and are thereby the most powerful tools to prevent further harm to our healthcare systems, economics and individual lives. This review summarizes the unprecedented pathways of vaccine development and approval during the ongoing SARS-CoV-2 pandemic. We focus on the real-world effectiveness and unexpected positive and negative side effects of the available vaccines and summarize the timeline of the applied adaptations to the recommended vaccination strategies in the light of emerging virus variants. Finally, we highlight upcoming strategies to improve the next generations of SARS-CoV-2 vaccines.

show abstract

“…However, a report looking at an outbreak of gamma among employees of a goldmine in French Guiana noted a “strikingly high attack rate” among people fully vaccinated with the Pfizer vaccine, as 60% of the fully vaccinated people became infected, compared with 75% of unvaccinated miners without a history of infection 12. The manufacturers of Sputnik V claim that it is “highly effective” against variants including gamma, but a study published in July looking at antibody responses found reduced neutralising activity against gamma and other variants 13…”

Section: Gammamentioning

confidence: 99%